Mathias Lukas
Charité
25 Papers
71 Citations
Mathias Lukas is an academic researcher from Charité. The author has contributed to research in topics: Medicine & Receptor. The author has an hindex of 8, co-authored 24 publications. Previous affiliations of Mathias Lukas include Siemens & Humboldt University of Berlin.
Chat about Author
Papers
Proof of Therapeutic Efficacy of a 177Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model.
Jörg Schulz,Martin Rohracker,Marvin Stiebler,Jürgen Goldschmidt,Franziska Stöber,Franziska Stöber,Mercedes Noriega,Anette Pethe,Mathias Lukas,Mathias Lukas,Frank Osterkamp,Ulrich Reineke,Aileen Höhne,Christiane Smerling,Holger Amthauer +14 more
TL;DR: The data demonstrate that the novel NTR1-targeting theranostic agent 3BP-227 is an effective and promising candidate for radioligand therapy, with a favorable preliminary safety profile and high potential for clinical translation.
45
Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution.
Güliz Acker,Anne Kluge,Mathias Lukas,Alfredo Conti,Alfredo Conti,Diana Pasemann,Franziska Meinert,Phuong Thuy Anh Nguyen,Claudius Jelgersma,Franziska Loebel,Volker Budach,Peter Vajkoczy,Christian Furth,Alexander D. J. Baur,Carolin Senger +14 more
TL;DR: This preliminary study supports the relevance of 68Ga-DOTATOC PET/MRI as a tool for radiosurgical treatment planning of meningiomas and demonstrates a relevant impact of PET/ MRI on target volume delineation of menediomas.
XTEN-Annexin A5: XTEN Allows Complete Expression of Long-Circulating Protein-Based Imaging Probes as Recombinant Alternative to PEGylation
Akvile Haeckel,Franziska Appler,Lena Figge,Harald Kratz,Mathias Lukas,Roger Michel,Jörg Schnorr,Marietta Zille,Bernd Hamm,Eyk Schellenberger +9 more
TL;DR: The presented method allows the expression and production of high amounts of long-circulating XTEN-AnxA5 without the necessity of PEGylation, thereby simplifying the synthesis while avoiding labeling-induced inactivation of AnxA 5 and potential adverse effects of P EG.
27
Brain perfusion SPECT in the mouse: normal pattern according to gender and age.
Ivayla Apostolova,Andreas Wunder,Ulrich Dirnagl,Roger Michel,Nina Stemmer,Mathias Lukas,Thorsten Derlin,Betina Gregor-Mamoudou,Jürgen Goldschmidt,Winfried Brenner,Ralph Buchert +10 more
TL;DR: High-resolution HMPAO SPECT indicates lateral asymmetry of r CBF in the mouse brain as well as age-related changes during late maturation and is a promising technique for measuring rCBF in preclinical research.
26
Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
Carolin Senger,Alfredo Conti,Alfredo Conti,Anne Kluge,Diana Pasemann,Markus Kufeld,Güliz Acker,Mathias Lukas,Arne Grün,Goda Kalinauskaite,Volker Budach,J. Waiser,Carmen Stromberger +12 more
TL;DR: Robotic SABR with motion tracking offers a valid treatment option for patients, who are at increased risk for progression to end-stage renal disease due to partial nephrectomy or ablative techniques, and is technically feasible for the treatment of RCC in preexisting kidney disease with good local tumor control at about 2 years follow-up.